Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

More Change With Less Hoopla To FDA Out-Of-Specification Investigations Policy

May 19 2022

• By Bowman Cox

Oulier — when outliers can be safely ignored • Source: Shutterstock

Related Content

US FDA And OMB Should ‘Pause’ Billion-Dollar Quality Metrics Program, Industry Groups Say

Mar 30 2017

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Jan 07 2019

The Baxter/Claris Warning Letter: Out Of Spec, Out Of Mind

Jul 24 2018

US FDA Warns Torrent Over Losartan Process Validation, OOS Invalidation Failures

Oct 17 2019

FDA Cites Lupin For Poor Quality Metric Performance

Jun 30 2017

The Quality Lowdown: More Inspection Delays, More Findings On Sterility And Investigations

Jan 23 2022

FDA’s Revised Quality Metrics Program: Voluntary Now, Mandatory Later

Nov 28 2016

Additional Topics

United States Manufacturing Quality Compliance BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window